Its unique design means that any treatment that appears to work for patients in the trial will be submitted for review to the Cancer Drug Fund (CDF)**** who will then decide whether to collect more data and assess whether the drug could be used as a routine treatment option on the NHS for patients with …
Opening of a precision medicine trial for rare cancers in adults and children Read More »
RADNOR, Pa., Nov. 20, 2022 (GLOBE NEWSWIRE) — The law firm Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is advising investors that a securities class action lawsuit has been filed in the District United States Court for the Central District of California v. Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT). The suit accuses Fulgent of violations …
RADNOR, Pa., November 18, 2022 /PRNewswire/ — The law firm Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) advises investors that a class action securities lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent” ) (NASDAQ: FLGT). The suit accuses Fulgent of violations of federal securities laws, including omissions and fraudulent misrepresentations regarding the company’s business, …
RADNOR, Pa., Nov. 13, 2022 (GLOBE NEWSWIRE) — The law firm Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is advising investors that a securities class action lawsuit has been filed in the District United States Court for the Central District of California v. Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT). The suit accuses Fulgent of violations …
NEW YORK, November 12, 2022 /PRNewswire/ — WHY: New York, November 12, 2022. Rosen Law Firm, a global investor rights law firm, reminds buyers of Fulgent Genetics, Inc. (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022both dates included (the “Class Period”), of the material November 21, 2022 lead applicant deadline. SO WHAT: …
RADNOR, Pa.–(BUSINESS WIRE)–The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) advises investors that a class action securities lawsuit has been filed against Fulgent Genetics, Inc. (“Fulgent”) ( NASDAQ: FLGT). The suit accuses Fulgent of violations of federal securities laws, including omissions and fraudulent misrepresentations regarding the company’s business, operations and prospects. Due …
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulgent Genetics, Inc. (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”), the important Deadline of November 21, 2022 for the main applicant. SO WHAT: …
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulgent Genetics, Inc. (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”), the important Deadline of November 21, 2022 for the main applicant. SO WHAT: …
